Brett Averso

Chief Technology Officer at EVQLV

Speaker

Brett Averso is the CTO and co-founder of EVQLV, a company leveraging advances in technology to evolve antibody design and engineering. As the architect behind EVQLV’s platform, Averso's work facilitated the computational prediction of 7 de novo binding antibodies shortly after the company's inception. Over the past 12 months, Averso has led 34 AI-powered antibody design and engineering projects between EVQLV and 22 organizations, including pharmaceutical companies, biotechs, and academic researchers. Averso expertise is in combining machine learning and antibody design, as well as quantitative evolutionary fitness, antibody structural modeling, representation learning, protein language models, scalable cloud computing, and immunoinformatics. He holds an M.S. in Data Science from Columbia University School of Engineering.